Osborne Clarke advised Fortino Capital on the deal. Fortino Capital invested in Addactis to accelerate the growth of this specialist in actuarial B2B SaaS software. Addactis succesfully...
You must be a Standard 1 Year member to access this content.
Osborne Clarke advised OncoDNA on the fundraising. OncoDNA announced its Round C financing of €6.5 million. Both private (including Vesalius BioCapital III, Ackermans & van Haaren,...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has advised Bone Therapeutics on the deal. Bone Therapeutics acquired a majority stake in Medsenic. This combination of Bone Therapeutics and Medsenic has created...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has assisted in the latest investment in Greenomy. Euroclear, a Belgium-based global provider of Financial Market Infrastructure (FMI) services, is the investor. The investment...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has advised Interel on the deal. Interel, an award-winning pan-European public affairs consultancy, has been acquired by Dentons Global Advisors. Interel has offices in...
You must be a Standard 1 Year member to access this content.
Osborne Clarke has advised Delphi Genetics on the deal. Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based...
You must be a Standard 1 Year member to access this content.
